HEPATOLOGY podcast

Player FM - Internet Radio Done Right

27 subscribers

Lagt til ten år siden

Innhold levert av AASLD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av AASLD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The Sarah Fraser Show

1
SISTER WIVES: The Brown Family Plans Garrison's Funeral, Gives NEW Details About His Passing. Justin Baldoni v Blake Lively UPDATES, First Pictures Of Micah Plath’s Broken Nose Have Surfaced!… 36:16

for 6 dager siden36:16

Spill senere

Lister

Lik

Likt

36:16

DANMMMMM…Have I got a show for you! First, a lot of Sister Wives tea - new rumors have surfaced Janelle Brown is leaving the show. Plus, Gabe Brown gives a life update after losing and tragically finding his brother Garrison dead. Sadly, Garrison took his own life in March 2024. Then we head over to discuss the new Welcome To Plathville tea. The first pictures of Micah Plath have surfaced after being beat up by his brother Issac and it doesn’t look good for the future of his modeling career. Lastly, we discuss the latest in the Justin Baldoni v Blake Lively case, Justin is back on social media and it was the perfect social media return. Timestamps: 00:00:00 - Open and new Sister Wives news 00:05:43 - Janelle Brown leaving the show? Sister Wives Closet is officially closed 00:12:45 - A new pic of Micah Plath’s broken nose has surfaced 00:18:18 - Justin Baldoni back on social media and Taylor Swifts team is pissed at Justin Baldoni MY Go Big Podcasting Courses Are Here! Purchase Go Big Podcasting and learn to start, monetize, and grow your own podcast. USE CODE: MOM15 for 15% OFF (code expires May 11th, 2025) **SHOP my Amazon Marketplace - especially if you're looking to get geared-up to start your own Podcast!!!** https://www.amazon.com/shop/thesarahfrasershow Show is sponsored by: Download Cash App & sign up! Use our exclusive referral code TSFS in your profile, send $5 to a friend within 14 days, and you’ll get $10 dropped right into your account. Terms apply Horizonfibroids.com get rid of those nasty fibroids Gopurebeauty.com science backed skincare from head to toe, use code TSFS at checkout for 25% OFF your order Nutrafol.com use code TSFS for FREE shipping and $10 off your subscription Rula.com/tsfs to get started today. That’s R-U-L-A dot com slash tsfs for convenient therapy that’s covered by insurance. SkylightCal.com/tsfs for $30 OFF your 15 inch calendar Quince.com/tsfs for FREE shipping on your order and 365 day returns Warbyparker.com/tsfs make an appointment at one of their 270 store locations and head to the website to try on endless pairs of glasses virtually and buy your perfect pair Follow me on Instagram/Tiktok: @thesarahfrasershow ***Visit our Sub-Reddit: reddit.com/r/thesarahfrasershow for ALL things The Sarah Fraser Show!!!*** Advertise on The Sarah Fraser Show: thesarahfrasershow@gmail.com Got a juicy gossip TIP from your favorite TLC or Bravo show? Email: thesarahfrasershow@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices…

HEPATOLOGY Podcast

Del

Serier hjem•Feed

Vision To Prevent and Cure Liver Disease Mission To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology. AASLD has grown to an international society responsible for all aspects of hepatology, and our annual meeting, The Liver Meeting®, has grown in attendance from 12 to over 9,500 physicians, surgeons, researchers, and allied health professionals from around the world. Hepatology has been recognized as a discipline only in the last few decades, and AASLD played a seminal and unifying role in focusing interest on hepatological problems, as well as the founding of other hepatological societies. Our three monthly journals, HEPATOLOGY, Liver Transplantation, and Clinical Liver Disease provide the latest research findings for hepatology and surgery of the liver. AASLD's membership includes ALL professionals dedicated to hepatobiliary discoveries and patient care. Mentoring, the sharing of knowledge, and dedication to professional growth and development are among the core values of AASLD and its members.

30 episoder

#Science #Stephen Harrison #AASLD

HEPATOLOGY Podcast

27 subscribers

updated for 9 år siden

Del

Serier hjem•Feed

30 episoder

#Science #Stephen Harrison #AASLD

Alle episoder

HEPATOLOGY Podcast

1
The Severity Of Steatosis Influences Liver Stiffness Measurement In Patients With NAFLD 7:24

for 9 years siden7:24

7:24

Drs. Stephen A. Harrison and Salvatore Petta discuss the paper: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease from the November 2015 issue of HEPATOLOGY.

HEPATOLOGY Podcast

1
Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection 10:41

for 9 years siden10:41

10:41

Note: Published earlier in 2015. Drs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.

HEPATOLOGY Podcast

1
Association of NAFLD with Subclinical Myocardial Remodeling and Dysfunction 11:17

for 10 years siden11:17

11:17

Drs. Stephen A. Harrison and Lisa B. VanWagner discuss the paper: Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.

HEPATOLOGY Podcast

1
The Role of Hepatic Resection in Liver Cancer 11:04

for 10 years siden11:04

11:04

Drs. Stephen A. Harrison and Sasan Roayaie discuss the paper: The Role of Hepatic Resection in the Treatment of Hepatocellular Cancer.

HEPATOLOGY Podcast

1
Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection 10:41

for 10 years siden10:41

10:41

Drs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.

HEPATOLOGY Podcast

1
The Impact of Phlebotomy in Nonalcoholic Fatty Liver Disease 11:25

for 10 years siden11:25

11:25

Drs. Stephen A. Harrison and Leon A. Adams discuss the paper: The Impact of Phlebotomy in Nonalcoholic Fatty Liver Disease: A Prospective, Randomized, Controlled Trial.

HEPATOLOGY Podcast

1
Portal Hypertension and the Outcome of Surgery for HCC 11:47

for 10 years siden11:47

11:47

Drs. Stephen A. Harrison and Annalisa Berzigotti discuss the paper: Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis from the Februrary issue of HEPATOLOGY.

HEPATOLOGY Podcast

1
Concordance Of Sustained Virological Response With Sofosbuvir - Containing Regimens For HCV 7:02

for 10 years siden7:02

7:02

Drs. Stephen A. Harrison and Eric M. Yoshida discuss the paper: Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus from the January issue of HEPATOLOGY.

HEPATOLOGY Podcast

1
Prioritizing HCC Patients -- Results Of The UNOS National Geographic Experiment 6:29

for 10 years siden6:29

6:29

Drs. Stephen A. Harrison and Karim J. Hazalun discuss the paper: Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment from the December issue of HEPATOLOGY.

HEPATOLOGY Podcast

1
Enhanced MRI Prognosis Of Early Early Stage HCC 10:54

for 10 years siden10:54

10:54

Stephen A. Harrison, MD and Taro Yamashita, MD, PhD, discuss Gd-EOB-DTPA-enhanced MRI and Alpha-fetoprotein Predict Prognosis of Early Early Stage HCC.

HEPATOLOGY Podcast

1
Ursodeoxycholic Acid and PSC, Revisited 9:55

for 11 years siden9:55

9:55

Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later. Liquid chromatography/tandem mass spectrometry was used for quantification of 29 plasma bile acid metabolites. Pruritus and health-related quality of life (HRQoL) were assessed with a 10-point numeric rating scale, the Medical Outcomes Study Short Form-36 (SF-36), and PBC-40 questionnaires. UDCA withdrawal resulted in a significant deterioration in liver biochemistry (increase of alkaline phosphatase of 75.6%; P?…

HEPATOLOGY Podcast

1
Kidney Biomarkers and Differential Diagnosis of Patients with Cirrhosis and Acute Kidney Injury 17:21

for 11 years siden17:21

17:21

Acute kidney injury (AKI) is common in patients with cirrhosis and associated with significant mortality. The most common etiologies of AKI in this setting are prerenal azotemia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS). Accurately distinguishing the etiology of AKI is critical, as treatments differ markedly. However, establishing an accurate differential diagnosis is extremely challenging. Urinary biomarkers of kidney injury distinguish structural from functional causes of AKI and may facilitate more accurate and rapid diagnoses. We conducted a multicenter, prospective cohort study of patients with cirrhosis and AKI assessing multiple biomarkers for differential diagnosis of clinically adjudicated AKI. Patients (n?=?36) whose creatinine returned to within 25% of their baseline within 48 hours were diagnosed with PRA. In addition, 76 patients with progressive AKI were diagnosed by way of blinded retrospective adjudication. Of these progressors, 39 (53%) patients were diagnosed with ATN, 19 (26%) with PRA, and 16 (22%) with HRS. Median values for neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and albumin differed between etiologies and were significantly higher in patients adjudicated with ATN. The fractional excretion of sodium (FENa) was lowest in patients with HRS, 0.10%, but did not differ between those with PRA, 0.27%, or ATN, 0.31%, P?=?0.54. The likelihood of being diagnosed with ATN increased step-wise with the number of biomarkers above optimal diagnostic cutoffs. Conclusion: Urinary biomarkers of kidney injury are elevated in patients with cirrhosis and AKI due to ATN. Incorporating biomarkers into clinical decision making has the potential to more accurately guide treatment by establishing which patients have structural injury underlying their AKI. Further research is required to document biomarkers specific to HRS.…

HEPATOLOGY Podcast

1
NASH and HCC: A Growing Role for Liver Transplantation 10:32

for 11 years siden10:32

10:32

Nonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation (LT) in the U.S. and is predicted to become the leading indication for LT in the near future. The trends in NASH-related hepatocellular carcinoma (HCC) among LT recipients in the U.S. remain undefined. We performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult LT recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry. From 2002-2012, there were 61,868 adults who underwent LT in the U.S., including 10,061 patients with HCC. The total number and proportion of HCC LT recipients demonstrated a significant increase following the implementation of the Model for Endstage Liver Disease (MELD) scoring system in 2002 (3.3%, n?=?143 in 2000 versus 12.2%, n?=?714 in 2005 versus 23.3%, n?=?1336 in 2012). The proportion of hepatitis C virus (HCV)-related HCC increased steadily from 2002 to 2012, and HCV remained the leading etiology of HCC throughout the MELD era (43.4% in 2002 versus 46.3% in 2007 versus 49.9% in 2012). NASH-related HCC also increased significantly, and NASH is the second leading etiology of HCC-related LT (8.3% in 2002 versus 10.3% in 2007 versus 13.5% in 2012). From 2002 to 2012, the number of patients undergoing LT for HCC secondary to NASH increased by nearly 4-fold, and the number of LT patients with HCC secondary to HCV increased by 2-fold. Conclusion: NASH is the second leading etiology of HCC leading to LT in the U.S. More important, NASH is currently the most rapidly growing indication for LT in patients with HCC in the U.S.…

HEPATOLOGY Podcast

1
Distinguishing Immunoglobulin G4-associated Cholangitis from PSC 13:14

for 11 years siden13:14

13:14

The recent addition of immunoglobulin (Ig)G4-associated cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chronic cholangiopathies has created the clinical need for reliable methods to discriminate between IAC and the more common cholestatic entities, primary (PSC) and secondary sclerosing cholangitis. The current American Association for the Study of Liver Diseases practice guidelines for PSC advise on the measurement of specific Ig (sIg)G4 in PSC patients, but interpretation of elevated sIgG4 levels remains unclear. We aimed to provide an algorithm to distinguish IAC from PSC using sIgG analyses. We measured total IgG and IgG subclasses in serum samples of IAC (n?=?73) and PSC (n?=?310) patients, as well as in serum samples of disease controls (primary biliary cirrhosis; n?=?22). sIgG4 levels were elevated above the upper limit of normal (ULN?=?>1.4 g/L) in 45 PSC patients (15%; 95% confidence interval [CI]: 11-19). The highest specificity and positive predictive value (PPV; 100%) for IAC were reached when applying the 4× ULN (sIgG4?>?5.6 g/L) cutoff with a sensitivity of 42% (95% CI: 31-55). However, in patients with a sIgG4 between 1× and 2× ULN (n?=?38/45), the PPV of sIgG4 for IAC was only 28%. In this subgroup, the sIgG4/sIgG1 ratio cutoff of 0.24 yielded a sensitivity of 80% (95% CI: 51-95), a specificity of 74% (95% CI: 57-86), a PPV of 55% (95% CI: 33-75), and a negative predictive value of 90% (95% CI: 73-97). Conclusion: Elevated sIgG4 (>1.4 g/L) occurred in 15% of patients with PSC. In patients with a sIgG4 >1.4 and <2.8 g/L, incorporating the IgG4/IgG1 ratio with a cutoff at 0.24 in the diagnostic algorithm significantly improved PPV and specificity. We propose a new diagnostic algorithm based on IgG4/IgG1 ratio that may be used in clinical practice to distinguish PSC from IAC.…

HEPATOLOGY Podcast

1
Ascites: Is the Etiology Cirrhosis or Cardiac? 12:02

for 11 years siden12:02

12:02

Heart failure (HF) is, after cirrhosis, the second-most common cause of ascites. Serum B-type natriuretic peptide (BNP) plays an important role in the diagnosis of HF. Therefore, we hypothesized that BNP would be useful in the differential diagnosis of ascites. Consecutive patients with new onset ascites were prospectively enrolled in this cross-sectional study. All patients had measurements of serum-ascites albumin gradient (SAAG), total protein concentration in ascitic fluid, serum, and ascites BNP. We enrolled 218 consecutive patients with ascites resulting from HF (n = 44), cirrhosis (n = 162), peritoneal disease (n = 10), and constrictive pericarditis (n = 2). Compared to SAAG and/or total protein concentration in ascites, the test that best discriminated HF-related ascites from other causes of ascites was serum BNP. A cutoff of >364 pg/mL (sensitivity 98%, specificity 99%, and diagnostic accuracy 99%) had the highest positive likelihood ratio (168.1); that is, it was the best to rule in HF-related ascites. Conversely, a cutoff ?182 pg/mL had the lowest negative likelihood ratio (0.0) and was the best to rule out HF-related ascites. These findings were confirmed in a 60-patient validation cohort. Conclusions: Serum BNP is more accurate than ascites analyses in the diagnosis of HF-related ascites. The workup of patients with new onset ascites could be streamlined by obtaining serum BNP as an initial test and could forego the need for diagnostic paracentesis, particularly in cases where the cause of ascites is uncertain and/or could be the result of HF.…

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.